Result card

  • EFF8: How does the use of FIT for CRC screening modify the symptoms and findings of adenomas and CRC?
English

How does the use of FIT for CRC screening modify the symptoms and findings of adenomas and CRC?

Authors: Jesús González-Enríquez, Francesca Gillespie, Stefania Lopatriello, Iñaki Imaz

Internal reviewers: Pseudo125 Pseudo125

Refer to domain search and domain methodology section.

A recent Italian screening programme by biennial immunochemical FOBT reported a retrospective comparison of cancer rate and stages between average risk screening participants and those who did not participate in the screening programme. Although the overall cancer rate was similar in the two populations (1.23 versus 1.20 per 1000 person-years), there were significant differences in TNM stage distribution between the two groups (stage III–IV cancers 0.24 versus 0.74 per 1000 respectively, p = 0.009).

This large cross-sectional study reported that colorectal cancers detected by immunochemical FOBT screening are identified at an earlier pathological stage, with significant prognostic and economic advantages to the populations screened {9}.

Optional
Partially
González-Enríquez J et al. Result Card EFF8 In: González-Enríquez J et al. Clinical Effectiveness In: Jefferson T, Cerbo M, Vicari N [eds.]. Fecal Immunochemical Test (FIT ) versus guaiac-based fecal occult blood test (FOBT) for colorectal cancer screening [Core HTA], Agenas - Agenzia nazionale per i servizi sanitari regionali; 2014. [cited 16 June 2021]. Available from: http://corehta.info/ViewCover.aspx?id=206

References